Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BB-1708
- Development stage
- Preclinical
- Lead developer
- 百力司康
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
01
Overview
BB-1708 is an antibody-drug conjugate (ADC) developed by Bliss Biopharmaceutical (Hangzhou) for the treatment of neoplasms, specifically solid tumors. As an ADC, it consists of a monoclonal antibody linked to a cytotoxic agent, designed to selectively deliver the cytotoxic payload to tumor cells expressing the target antigen. The drug is currently in preclinical development and has not yet entered clinical trials or received regulatory approval[1][2]. Detailed information about its specific molecular target, payload, and linker technology has not been disclosed publicly.
Beyond the preview
Go deeper on BB-1708.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BB-1708.